Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220529 · ClinicalTrials.gov registry record · NA
A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT03220529: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03220529 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03220529, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if the new Brillouin Ocular Scanner can measure the variation (difference) of the corneal elastic changes involved in the onset of corneal ectasia, induced by LASIK surgery and cornea collagen crosslinking (CXL) treatment. Ectasia refers to the thinning and bulging of the cornea and results in severe vision degradation (loss), which may occur because of a progressive disease (keratoconus) or because of LASIK surgery. It is believed that the structural weakening of the cornea plays a major role in developing ectasia. CXL is a treatment that is able to halt the progression of ectasia. The Brillouin Ocular Scanner is a technique based on the principles used in the laser speed measuring of a car (radar gun). When laser light illuminates a moving sample, a portion of the light slightly changes color. In our body, e.g in eye and corneal tissue, very weak sound waves are naturally present and they can induce a similar color shift. Measuring this color shift with a sensitive light color meter (spectrometer), we will measure the sound speed in the tissue.
Interventions
- DEVICE Brillouin Ocular Scanner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220529
The ClinicalTrials.gov registry entry for NCT03220529 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brillouin Ocular Scanner is the first listed.
NCT03220529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220529 about?
NCT03220529 is a clinical study titled "A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea". The purpose of this research study is to find out if the new Brillouin Ocular Scanner can measure the variation (difference) of the corneal elastic changes involved in the onset of corneal ectasia, induced by LASIK surgery and cornea collagen crosslinking (CXL) treatment. Ectasia refers to the thinn...
What is the current status of trial NCT03220529?
This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2016-11. Estimated completion is 2020-09.
What interventions are being tested in trial NCT03220529?
The interventions under investigation include: Brillouin Ocular Scanner (DEVICE).
Who is sponsoring clinical trial NCT03220529?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.